Eua for Regen-Cov Now Includes COVID-19 Postexposure Prophylaxis.

Area of Science:

• Immunology
• Virology
• Public Health

Background:

• The COVID-19 pandemic necessitates effective prevention strategies.
• Monoclonal antibodies offer a targeted approach to viral infections.
• Identifying individuals at high risk for severe COVID-19 is crucial for intervention.

Purpose of the Study:

• To summarize the revised emergency use authorization for REGEN-COV.
• To outline the indication for REGEN-COV as postexposure prophylaxis.
• To clarify the target population for this preventive measure.

Main Methods:

• Review of the updated emergency use authorization (EUA) for REGEN-COV.
• Identification of the specific criteria for postexposure prophylaxis eligibility.
• Confirmation of the age and risk stratification for the intended population.

Main Results:

• REGEN-COV (casirivimab and imdevimab) is authorized for postexposure prophylaxis.
• The indication applies to adults and children aged 12+ at high risk of severe COVID-19.
• This prophylaxis is an adjunct to, not a substitute for, COVID-19 vaccination.

Conclusions:

• The revised EUA expands the utility of REGEN-COV for COVID-19 prevention.
• Postexposure prophylaxis with REGEN-COV provides an additional tool for high-risk populations.
• Vaccination remains the primary strategy for preventing COVID-19.